Promises and Obstacles for the Blockade of CD40–CD40L Interactions in Allotransplantation
XL Li, S Ménoret, B Le Mauff, M Angin, I Anegon - Transplantation, 2008 - journals.lww.com
XL Li, S Ménoret, B Le Mauff, M Angin, I Anegon
Transplantation, 2008•journals.lww.comAlthough clinical trials using anti-CD40L mAb have been halted, blockade of CD40–CD40L
interactions has given promising results in rodent and nonhuman primate models. Recently,
new insights into the consequences of blocking CD40–CD40L interactions have led to the
possibility of overcoming the thromboembolic complications previously associated with this
strategy and may pave the way for successful tolerance induction. This mini review will
address the issues relating to CD40–CD40L blockade in allotransplantation.
interactions has given promising results in rodent and nonhuman primate models. Recently,
new insights into the consequences of blocking CD40–CD40L interactions have led to the
possibility of overcoming the thromboembolic complications previously associated with this
strategy and may pave the way for successful tolerance induction. This mini review will
address the issues relating to CD40–CD40L blockade in allotransplantation.
Abstract
Although clinical trials using anti-CD40L mAb have been halted, blockade of CD40–CD40L interactions has given promising results in rodent and nonhuman primate models. Recently, new insights into the consequences of blocking CD40–CD40L interactions have led to the possibility of overcoming the thromboembolic complications previously associated with this strategy and may pave the way for successful tolerance induction. This mini review will address the issues relating to CD40–CD40L blockade in allotransplantation.
Lippincott Williams & Wilkins